Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Dec 02, 2024 7:30am

101 Views

Post# 36340267

RE:RE:RE:RE:RE:New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Go figure why a company entertaining the risk of loosing it's main source of revenu and possibly cripple the shareholders once again thanks to their lack of prudence is increasing overhead. One has to speculate they are expecting something positive. But from the shareholder point of view it makes absolutly no sense.

<< Previous

Bullboard Posts

Next >>

Nintendo stock hits new all-time high as excitement builds over Switch successor